The Viz.ai platform includes several specialized solutions such as Viz.ai One™, Viz Neuro Suite, Viz Vascular Suite, Viz Cardio Suite, Viz Trauma Suite, Viz Radiology Suite, and Viz Life Sciences. This business doubled over the prior 18 months to reach 13 strategic partnerships, with 6 new pharma partnerships added in 2025 alone, allowing pharmaceutical companies to accelerate product launches and improve patient access to new therapies. The company has established multi-year partnerships with major pharmaceutical companies to deploy disease-specific AI workflows, including Sanofi and Regeneron for AI-powered COPD workflows and Novartis for oncology workflows.
Cyborg Score Rationale
Viz.ai has achieved profitability, secured $289M+ in funding, deployed over 50 FDA-cleared algorithms, and established strategic partnerships with leading pharma companies. Recent product launches (Pulmonary Suite in May 2026, Agent Studio in March 2026) and clinical validation (44% reduction in stroke transfer times in March 2026) demonstrate strong market traction and clinical impact. The company is expanding beyond hospitals into pharma distribution.
Top Insights
(May 2026) Launched Viz Pulmonary Suite, first comprehensive AI-powered solution dedicated to pulmonary care delivery
(March 2026) Real-world data showed 44% reduction in door-in-door-out transfer time for LVO stroke patients and 84% reduction in CTA-to-detection time
(March 2026) Launched Viz Agent Studio enabling health systems to build and scale their own AI care pathways
(May 2026) Achieved ISO/IEC 42001 Certification for Agentic AI in healthcare; ranked #1 for second consecutive year in 2026 Black Book Survey
Named Competitors
Medidata Platform — Clinical trial and life sciences data platform
IQVIA Platform — Clinical research and healthcare intelligence services
Verily Health AI — Healthcare AI and clinical decision support
Recent Developments
(May 2026) Launched Viz Pulmonary Suite for pulmonary care delivery
(May 2026) Achieved ISO/IEC 42001 Certification, setting standard for Agentic AI in healthcare
(April 2026) Won Gold Edison Award for advancing AI-driven clinical workflows in hemorrhage care
(March 2026) Published real-world data demonstrating 44% reduction in stroke transfer time
(March 2026) Launched Viz Agent Studio and partnership with Alnylam for cardiac amyloidosis AI pathway
Open the full interactive Viz.ai, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.